Glenmark Pharmaceuticals recalled 44,328 bottles of Carvedilol Tablets, USP, 3.125 mg on August 7, 2025. The recall follows the discovery of N-Nitroso Carvedilol I impurity above acceptable levels. Consumers should stop using this medication immediately and consult their healthcare providers.
CGMP Deviations: Presence of a nitrosamine, N-Nitroso Carvedilol I Impurity above the current Acceptable Intake Level.
Consumers and healthcare providers should stop using this product immediately. Contact Glenmark Pharmaceuticals Inc., USA or your healthcare provider for guidance. Notification method: Letter
Get instant alerts for Health & Personal Care recalls
Be the first to know. Free instant alerts to your inbox.
The recall includes Carvedilol Tablets in 500-count bottles (NDC 68462-162-05) and 100-count bottles (NDC 68462-162-01). These products were distributed nationwide in the USA and manufactured by Glenmark Pharmaceuticals Ltd in Goa, India.
The recall was issued due to CGMP deviations resulting in the presence of N-Nitroso Carvedilol I, a nitrosamine impurity. This impurity is above the current acceptable intake level, which poses potential health risks to consumers.
No specific injuries or incidents have been reported related to this recall. The FDA classified this recall as Class II, indicating a potential health hazard.
Consumers and healthcare providers should stop using the affected Carvedilol Tablets immediately. Contact Glenmark Pharmaceuticals Inc. or your healthcare provider for further guidance and to discuss possible alternatives.
For more information, consumers can call Glenmark Pharmaceuticals Inc. or visit their official website. The recall notification has also been sent via letter.
Get instant alerts for recalls that affect you. Free forever.
Taro Pharmaceuticals announced a market withdrawal of Diclofenac Sodium, Topical Gel, 3% on January 27, 2026. The withdrawal stems from out of specification viscosity results. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,057 bags of Acyclovir Sodium Injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers should cease use immediately and contact the manufacturer for guidance.
Fresenius Kabi Compounding recalled its vancomycin HCl injection on February 5, 2026, due to a lack of assurance of sterility. This Class II recall affects all lots distributed nationwide. Healthcare providers and consumers must stop using the product immediately.
Fresenius Kabi Compounding recalled 1,578 bags of vancomycin HCl injection on February 5, 2026. The company cited a lack of assurance of sterility as the reason for the recall. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,410 bags of ketamine HCl injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers and consumers must stop using this product immediately.
Fresenius Kabi Compounding recalled 10,548 bags of thiamine HCl injection on February 5, 2026. The recall follows a lack of assurance of sterility, posing a high health risk. Affected products include several lots expiring between February and May 2026.
Pro Numb Tattoo Numbing Spray was recalled due to cGMP deviations. The recall affects products distributed nationwide in the USA. Consumers should stop using the spray immediately and contact Pro Numb Tattoo Numbing Spray LLC for guidance.
Pro Numb Tattoo Numbing Spray was recalled on February 2, 2026 due to cGMP deviations. The product, containing 4% lidocaine, is distributed by Pro Numb Tattoo Numbing Spray LLC. Consumers should stop using it immediately and contact the company for further guidance.